

Everstone Capital sells majority stake in Rubicon Research Pvt. Ltd. to General Atlantic Partners

Torreya served as financial advisor to Everstone and Rubicon Research

Mumbai, India, April 4, 2019

Everstone Capital, a premier invest group focused on India and South East Asia, sold their majority stake in Rubicon Research Pvt. Ltd., a specialty generics pharmaceutical product development company, to General Atlantic Partners, a leading investment firm focused on growth equity.

Rubicon Research is engaged in the research, development, and manufacturing of generic and specialty pharmaceutical formulations for the global market using its proprietary manufacturing and drug delivery technologies. Everstone entered Rubicon as an investor in 2016, providing an exit to the incumbent investor, and infusing primary capital to help Rubicon scale its R&D and manufacturing.

Torreya served as financial advisor to Everstone Capital and Rubicon Research for this transaction, as well as the original transaction in 2016, demonstrating Torreya's long-term commitment to helping our clients achieve their goals. Torreya has advised on nearly 40 transactions, including 11 financings, in the healthcare industry since the beginning of 2018.

ABOUT RUBICON RESEARCH PVT. LTD.

For more information about Rubicon, please see: www.rubicon.co.in

ABOUT EVERSTONE CAPITAL

For more information about Everstone, please see: www.everstonecapital.com

ABOUT GENERAL ATLANTIC PARTNERS

For more information about General Atlantic, please see: www.generalatlantic.com



Torreya Contact

NITIN LATH

Managing Director | Mumbai Office

nitin.lath@torreya.com | +91 22 6127 1191 | torreya.com

Torreya is a global advisory firm serving the life sciences industry. Please visit torreya.com for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 150 Aldersgate Street, London EC1A 4AB. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.